Active placebo control groups of pharmacological interventions were rarely used but merited serious consideration: a methodological overview

Journal of Clinical Epidemiology

Volumn 87, Issue , 2017, Pages 35-46

  Jensen, Jakob Solgaard ^a   Bielefeldt, Andreas Ørsted ^a   Hróbjartsson, Asbjørn ^a,b  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Active placebo; Blinding; Methodological overview; Placebo; Randomised clinical trials

Indexed keywords

ANTIHISTAMINIC AGENT; BENZATROPINE; BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DIPHENHYDRAMINE; PLACEBO; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR; DRUG;

ARTICLE; CROSSOVER PROCEDURE; DEPRESSION; DRUG SCREENING; HUMAN; OBSERVATIONAL STUDY; PAIN; PREVALENCE; PRIORITY JOURNAL; RANDOM SAMPLE; RISK REDUCTION; SIDE EFFECT; THERAPY EFFECT; CONTROL GROUP; METHODOLOGY; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS AND NUMERICAL DATA;

CONTROL GROUPS; HUMANS; PHARMACEUTICAL PREPARATIONS; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 85019737695     PISSN: 08954356     EISSN: 18785921     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2017.03.001     Document Type: Article

References (51)

1. Hrobjartsson, A., Emanuelsson, F., Skou Thomsen, A.S., Hilden, J., Brorson, S., Bias due to lack of patient blinding in clinical trials. A systematic review of trials randomizing patients to blind and nonblind sub-studies. Int J Epidemiol 43 (2014), 1272–1283.
2. Hróbjartsson, A., Thomsen, A.S.S., Emanuelsson, F., Tendal, B., Hilden, J., Boutron, I., et al. Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors. BMJ, 344, 2012, e1119.
3. Bello, S., Moustgaard, H., Hróbjartsson, A., The risk of unblinding was infrequently and incompletely reported in 300 randomized clinical trial publications. J Clin Epidemiol 67 (2014), 1059–1069.
4. Başoğlu, M., Marks, I., Livanou, M., Swinson, R., Double-blindness procedures, rater blindness, and ratings of outcome. Observations from a controlled trial. Arch Gen Psychiatry 54 (1997), 744–748.
5. Bystritsky, A., Waikar, S.V., Inert placebo versus active medication. Patient blindability in clinical pharmacological trials. J Nerv Ment Dis 182:9 (1994), 485–487.
6. Marini, J.L., Sheard, M.H., Bridges, C.I., Wagner, E., An evaluation of the double-blind design in a study comparing lithium carbonate with placebo. Acta Psychiatr Scand 53 (1976), 343–354.
7. Margraf, J., Ehlers, A., Roth, W.T., Clark, D.B., Sheikh, J., Agras, W.S., et al. How “blind” are double-blind studies?. J Consult Clin Psychol 59:1 (1991), 184–187.
8. Brownell, K.D., Stunkard, A.J., The double-blind in danger: untoward consequences of informed consent. Am J Psychiatry 139:11 (1982), 1487–1489.
9. Shah, E., Triantafyllou, K., Hana, A.A., Pimentel, M., Adverse events appear to unblind clinical trials in irritable bowel syndrome. Neurogastroenterology Motil 26 (2014), 482–488.
10. Luckenbaugh, D.A., Niciu, M.J., Ionescu, D.F., Nolan, N.M., Richards, E.M., Brutsche, N.E., et al. Do the dissociative side effects of ketamine mediate its antidepressant effects?. J Affect Disord 159 (2014), 56–61.
11. Moncrieff, J., Wessely, S., Hardy, R., Active placebos versus antidepressants for depression. Cochrane Database Syst Rev(1), 2004 Art. No.: CD003012.
12. Thomson, R., Side effects and placebo amplification. Br J Psychiatry 140 (1982), 64–68.
13. Lasagna, L., Meier, P., Clinical evaluation of drugs. Annu Rev Med 9 (1958), 347–354.
14. AIM-HIGH Investigators. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH). Am Heart J 161 (2011), 538–543.
15. Atkinson, J., Slater, M., Wahlgren, D., Effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity. Pain 83:2 (1999), 137–145.
16. Atkinson, J.H., Slater, M.A., Capparelli, E.V., Wallace, M.S., Zisook, S., Abramson, I., et al. Efficacy of noradrenergic and serotonergic antidepressants in chronic back pain: a preliminary concentration-controlled trial. J Clin Psychopharmacol 27 (2007), 135–142.
17. Max, M., Lynch, S., Muir, J., Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 326 (1992), 1250–1256.
18. Salamone, J.D., A critique of recent studies on placebo effects of antidepressants: importance of research on active placebos. Psychopharmacology 152 (2000), 1–6.
19. Edward, S.J.L., Stevens, A.J., Braunholtz, D.A., Lilford, R.J., Swift, T., The ethics of placebo-controlled trials: a comparison of inert and active placebo controls. World J Surg 29 (2005), 610–614.
20. Kirsch, I., St John's wort, conventional medication, and placebo: an egregious double standard. Complement Therapies Med 11:3 (2003), 193–195.
21. Kirsch, I., Antidepressants and the placebo effect. Z Psychol 222:3 (2014), 128–134.
22. Fisher, S., Greenberg, R., Examining antidepressant effectiveness: findings, ambiguities, and some vexing puzzles. Fisher, S., Greenberg, R., (eds.) The limits of biological treatments for psychological distress, 1989, Hillsdale, Erlbaum, NJ pp. 1-37.
23. Howick, J., Questioning the methodologic superiority of “placebo” over “active” controlled trials. Am J Bioeth 9 (2009), 34–48.
24. Kirsch, I., Sapirstein, G., Listening to Prozac but hearing placebo: a meta-analysis of antidepressant medication. Prev Treat, 1, 1998 Article 0002a.
25. Rief, W., Glombiewski, J.A., The hidden effects of blinded, placebo-controlled randomized trials: an experimental investigation. Pain 153:12 (2012), 2473–2477.
26. Cooney, J.M., Active placebos in antidepressant trials. Br J Psychiatry 172 (1998), 541b–542b.
27. Gross, H., Ebert, M.H., Faden, V.B., Goldberg, S.C., Kaye, W.H., Caine, E.D., et al. A double-blind trial of 9-tetrahydrocannabinol in primary anorexia nervosa. J Clin Psychopharmacol 3 (1983), 165–171.
28. Enck, P., Weimer, K., Klosterhalfen, S., Balanced placebo design, active placebos and other design features for identifying, minimizing and characterizing the placebo response. Luana, Colloca, Magne, Flaten, Karin, Meissner, (eds.) Placebo and Pain - From Bench to Bedside, 2013, Academic Press pp. 159–173.
29. Boutron, I., Estellat, C., Guittet, L., Dechartres, A., Sackett, D.L., Hróbjartsson, A., et al. Methods of blinding in reports of randomized controlled trials assessing pharmacologic treatments: a systematic review. PLos Med, 3(10), 2006, e425.
30. Wartolowska, K., Judge, A., Hopewell, S., Collins, G.S., Dean, B.J.F., Rombach, I., et al. Use of placebo controls in the evaluation of surgery: systematic review. BMJ, 348, 2014, g3253.
31. Quitkin, F., Rabkin, J., Validity of clinical trials of antidepressants. Am J Psychiatry 157 (2000), 327–337.
32. Max, M.B., Schafer, S.C., Culnane, M., Dubner, R., Gracely, R.H., Association of pain relief with drug side effects in postherpetic neuralgia: a single-dose study of clonidine, codeine, ibuprofen, and placebo. Clin Pharmacol Ther 43 (1988), 363–371.
33. Cohen, D., Jacobs, D.H., Randomized controlled trials of antidepressants: clinically and scientifically irrelevant. Debates Neurosci 1:1 (2007), 44–54.
34. Gaudiano, B.A., Herbert, J.D., Methodological issues in clinical trials of antidepressant medications: perspectives from psychotherapy outcome research. Psychother Psychosom 74 (2005), 17–25.
35. Fisher, S., Greenberg, R., How sound is the double-blind design for evaluating psychotropic drugs?. J Nervous Ment Dis 181 (1993), 345–350.
36. Moncrieff, J., Are antidepressants overrated? A review of methodological problems in antidepressant trials. J Nervous Ment Dis 189 (2001), 1–10.
37. Thase, M.E., The small specific effects of antidepressants in clinical trials: what do they mean to psychiatrists?. Curr Psychiatry Rep 13 (2011), 476–482.
38. Berman, R.M., Narasimhan, M., Miller, H.L., Anand, A., Cappiello, A., Oren, D.A., et al. Transient depressive relapse induced by catecholamine depletion: potential phenotypic vulnerability marker?. Arch Gen Psychiatry 56 (1999), 395–403.
39. Berman, R.M., Sanacora, G., Anand, A., Roach, L.M., Fasula, M.K., Finkelstein, C.O., et al. Monoamine depletion in unmedicated depressed subjects. Biol Psychiatry 51 (2002), 469–473.
40. Bremner, J.D., Vythilingam, M., Ng, C.K., Vermetten, E., Nazeer, A., Oren, D.A., et al. Regional brain metabolic correlates of alpha-methylparatyrosine-induced depressive symptoms: implications for the neural circuitry of depression. JAMA 289 (2003), 3125–3134.
41. Cassidy, F., Weiner, R.D., Cooper, T.B., Carroll, B.J., Combined catecholamine and indoleamine depletion following response to ECT. Br J Psychiatry 196 (2010), 493–494.
42. Delgado, P.L., Miller, H.L., Salomon, R.M., Licinio, J., Heninger, G.R., Gelenberg, A.J., et al. Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants. Psychopharmacol Bull 29 (1993), 389–396.
43. Miller, H., Delgado, P., Effects of α-methyl-para-tyrosine (AMPT) in drug-free depressed patients. Neuropsychopharmacology 14 (1996), 151–157.
44. Neumeister, A., Turner, E.H., Matthews, J.R., Postolache, T.T., Barnett, R.L., Rauh, M., et al. Effects of tryptophan depletion vs catecholamine depletion in patients with seasonal affective disorder in remission with light therapy. Arch Gen Psychiatry 55 (1998), 524–530.
45. Lam, R.W., Tam, E.M., Grewal, A., Yatham, L.N., Effects of alpha-methyl-para-tyrosine- induced catecholamine depletion in patients with seasonal affective disorder in summer remission. Neuropsychopharmacology 25:5 suppl (2001), 97–101.
46. Murrough, J., Iosifescu, D., Chang, L.C., Jurdi, R.K., Green, C.E., Perez, A.M., et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 170 (2013), 1134–1142.
47. Price, R.B., Iosifescu, D.V., Murrough, J.W., Chang, L.C., Al Jurdi, R.K., Iqbal, S.Z., et al. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress Anxiety 31:4 (2014), 335–343.
48. Giannini, A.J., Malone, D.A., Giannini, M.C., Price, W.A., Loiselle, R.H., Treatment of depression in chronic cocaine and phencyclidine abuse with desipramine. J Clin Pharmacol 26 (1986), 211–214.
49. Hewlett, W.A., Vinogradov, S., Agras, W.S., Clomipramine, clonazepam, and clonidine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 12 (1992), 420–430.
50. Dakwar, E., Anerella, C., Hart, C.L., Levin, F.R., Mathew, S.J., Nunes, E.V., Therapeutic infusions of ketamine: do the psychoactive effects matter?. Drug Alcohol Depend 136 (2014), 153–157.
51. Kirsch, I., Moore, T.J., Scoboria, A., Nicholls, S.S., The emperor's new drugs: an analysis of antidepressant medication data submitted to the U.S. Food and Drug Administration. Prev Treat, 5(1), 2002 article 23.